Chemotherapy News and Research

Latest Chemotherapy News and Research

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

The George W. Bush Institute is forming a public-private partnership to use PEPFAR's existing infrastructure of doctors, nurses and clinics to expand screening and treatment of women for cervical cancer and perform breast cancer education in the developing world, the Wall Street Journal reports.

13 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

Chemotherapy before or after breast-conserving therapy does not impact treatment success

Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, according to a study by researchers at The University of Texas MD Anderson Cancer Center.

9 Sep 2011

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor.

9 Sep 2011

Maxygen increases stock repurchase program to $20 million

Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.

8 Sep 2011

Researchers identify bouncer protein that plays a vital role in RA prevention

Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

8 Sep 2011

Scientists invent new system that uses magnetism to purify hybrid nanoparticles

A team of Penn State University scientists has invented a new system that uses magnetism to purify hybrid nanoparticles -- structures that are composed of two or more kinds of materials in an extremely small particle that is visible only with an electron microscope.

8 Sep 2011

New study to better understand relapsed medulloblastoma in children

Children with medulloblastoma, (a type of malignant brain tumour), undergo extensive and debilitating treatment, which has led to marked improvements in survival rates over recent decades. Despite this, these tumours will return in a proportion of patients following treatment (termed relapse), and the vast majority of these will succumb to their disease.

8 Sep 2011

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Cancer Research UK's Drug Development Office has opened a trial of a new combination of drugs for the treatment of patients with brain cancer.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

IBCRF awards TGen $50,000 to discover genetic origins of inflammatory breast cancer

The Inflammatory Breast Cancer Research Foundation (IBCRF) has awarded $50,000 to the Translational Genomics Research Institute (TGen) to discover the genetic origins of this rare and most deadly form of breast cancer.

7 Sep 2011

Chemotherapy linked to speech difficulties among cancer patients

Patients who have received high doses of chemotherapy may find it harder to express themselves verbally, according to new research from the Sahlgrenska Academy at the University of Gothenburg, Sweden. Speech difficulties among cancer patients who received chemotherapy treatment were two times higher than among those who did not.

7 Sep 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

LC-MRM could provide better understanding of multiple myeloma drug resistance

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

Chemotherapy before or after breast-conserving therapy does not impact treatment success

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Maxygen increases stock repurchase program to $20 million

Researchers identify bouncer protein that plays a vital role in RA prevention

Scientists invent new system that uses magnetism to purify hybrid nanoparticles

New study to better understand relapsed medulloblastoma in children

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

IBCRF awards TGen $50,000 to discover genetic origins of inflammatory breast cancer

Chemotherapy linked to speech difficulties among cancer patients

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in